Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : GENA-104
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Ellipses Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Ellipses In-Licences GENA-104 A Novel Immuno-Oncology Agent
Details : Under the licensing agreement with Genome, Ellipses will take responsibility for all future clinical development of EP0089 (GENA-104) for the treatment of cancer.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
February 11, 2025
Lead Product(s) : GENA-104
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Ellipses Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Ibuprofen
Therapeutic Area : Neurology
Study Phase : Approved FDF
Recipient : Undisclosed
Deal Size : Undisclosed
Deal Type : Acquisition
Genomma Lab Announces Strategic Bolt-On Acquisition of Four Brands
Details : Genomma acquired the IBU 400 and Treg brands which enables Genomma to enter the ibuprofen segment, the second largest analgesics category, further strengthening the Company's position.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 25, 2024
Lead Product(s) : Ibuprofen
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Recipient : Undisclosed
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Debiopharm
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Debiopharm And Genome & Company Partner On Novel Oncology ADC Family
Details : Debiopharm is granted exclusive global rights to use Genome & Company’s antibodies to develop potential first-in-class ADCs integrating Debiopharm’s Multilink™ technology to treat cancers.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 06, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Debiopharm
Deal Size : Undisclosed
Deal Type : Licensing Agreement
A First-in-human Study of GENA-104A16 in Patients With Advanced Solid Tumors
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 01, 2024
Lead Product(s) : GEN-001
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
August 21, 2023
Lead Product(s) : GEN-001
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GEN-001,Avelumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Positive Results from Interim Analysis of 'GEN-001' Plus Avelumab (Bavencio®) Phase II Trial
Details : GEN-001 is being developed as an orally administered microbiome therapeutic with Lactococcus lactis, a single strain bacteria isolated from a healthy human. Its anticancer efficacy was proven by activating immune activity of cancer cells.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
May 19, 2023
Lead Product(s) : GEN-001,Avelumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GEN-001
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Merck Group
Deal Size : Inapplicable
Deal Type : Inapplicable
GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
June 15, 2022
Lead Product(s) : GEN-001
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Merck Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GEN-001,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Upon the execution of the agreement, Genome will conduct a phase 2 clinical trial to evaluate the safety and efficacy of its immuno-oncology microbiome therapeutic, GEN-001, in combination with MSD’s anti-PD-1 therapy, KEYTRUDA®, in patients with bili...
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Undisclosed
March 03, 2022
Lead Product(s) : GEN-001,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Recipient : Oramed Pharmaceuticals
Deal Size : $20.0 million
Deal Type : Collaboration
Details : Genomma Lab is expected to contribute resources to the joint venture’s oral COVID-19 vaccine development, as well as clinical, regulatory, and commercial activities in Mexico.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
November 18, 2021
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Recipient : Oramed Pharmaceuticals
Deal Size : $20.0 million
Deal Type : Collaboration
Lead Product(s) : GEN-001,Avelumab
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Merck Group
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration follows in just a year after signing the first agreement with Merck KGaA, Darmstadt, Germany and Pfizer in December 2019 to conduct the first combination clinical trial of avelumab (BAVENCIO®) and GEN-001.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Undisclosed
September 03, 2021
Lead Product(s) : GEN-001,Avelumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Merck Group
Deal Size : Undisclosed
Deal Type : Collaboration